Genprex is working on developing its initial drug candidate for NSCLC that would potentially benefit a large patient population who cannot currently benefit from approved therapies.
Genprex today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Earlier this month, Genprex’s President and Chief Operating Officer, Julien Pham attended the American Society of Gene & Cell Therapy’s 22nd Annual Meeting in Washington, D.C.
Gene therapy is a big and trending topic in the world of medicine and has recently been making headlines as large pharmaceutical companies have been ramping up acquisitions of gene therapy companies. So how exactly does gene therapy work?
Genprex reported that its collaborators from The University of Texas MD Anderson Cancer Center presented positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a poster presented at the American Association of Cancer Research Meeting 2019.
Genprex today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission.
The gene therapy market is experiencing tremendous excitement, and these acquisitions strengthen the position that gene therapy is now a significant and key treatment option for patients with serious diseases or cancer.
Genprex today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019.